On February 19, 2010 an article written by Gardiner Harris of the New York Times regarding Avandia was featured on MSNBC. Apparently the New York Times obtained FDA reports where the issue as to whether or not Avandia should be completely removed from the marketplace was discussed. As stated in the article,
“The internal F.D.A. reports are part of a fierce debate within the agency over what to do about Avandia, manufactured by GlaxoSmithKline.”
Avandia’s connection with heart attacks, heart failure and possible death has been under review for quite some time. The article goes on to point out,
“The battle has been brewing for years but has been brought to a head by disagreement over a new clinical trial and a Senate investigation that concluded that GlaxoSmithKline should have warned patients earlier of the drug’s potential risks.”
To put the concerns in perspective, the article discusses more of what is contained in the FDA reports. The article states,
“The reports, obtained by The New York Times, say that if every diabetic now taking Avandia were instead given a similar pill Actos, about 500 heart attacks and 300 cases of heart failure would be averted every month because Avandia can hurt the heart. Avandia, intended to treat Type 2 diabetes, is known as rosiglitazone and was linked to 304 death during the third quarter of 2009”
It will be interesting to see what the FDA decides to do regarding the marketing of Avandia. To read the New York Times article in its entirety we have attached the following link: http://bit.ly/AvandiaNYTArticle
the post seems to be very good and very much helpful to the people who are fed up with repeated searches for these kind of posts. Thank you very much.
I bookmarked this web address a while ago because of the interesting content and I have never been unsatisfied. Continue the outstanding work.